ArticleJournal of current ophthalmology
Short-Term Outcomes of Gonioscopy-Assisted Transluminal Trabeculotomy in Patients with Advanced Glaucoma.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To review the results of gonioscopy-assisted transluminal trabeculotomy (GATT) in patients with advanced glaucoma. GATT has shown efficacy in mild to moderate cases of glaucoma. Its efficacy in advanced glaucoma is uncertain, though recent studies show promising short-term outcomes. Methods: A retrospective chart review of advanced glaucoma patients undergoing GATT with or without cataract surgery from January 2018 to April 2023 was conducted. Complete success was defined as intraocular pressure (IOP) <14 mmHg with ≥30% reduction from baseline (Criteria A) or IOP <18 mmHg and/or ≥20% reduction (Criteria B), without antiglaucoma medications. Qualified success was defined as attainment of the same with a maximum of 2 medications. Results: A total of 69 eyes from 60 patients (mean age, 61.2 ± 15.3 years) were included in the study. The mean IOP decreased from 24.9 ± 10.7 mmHg preoperatively to 12.1 ± 3.0 mmHg at 6 months postoperatively. At 6 months, the complete success rate (based on Criteria A) was 66.7%, with an overall success rate of 81.9%. By 1 year ( Conclusions: GATT demonstrates encouraging short-term outcomes in advanced glaucoma, particularly in treatment-naïve patients and those undergoing combined cataract surgery. However, delayed bleeds can lead to IOP spikes and treatment failure. GATT may be considered as a viable surgical option in treatment naïve patients with advanced glaucoma. Its efficacy is bolstered when combined with cataract surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.